Profile data is unavailable for this security.
About the company
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
- Revenue in USD (TTM)322.67m
- Net income in USD-60.51m
- Incorporated2016
- Employees1.32k
- LocationFulgent Genetics Inc4399 SANTA ANITA AVEEL MONTE 91731United StatesUSA
- Phone+1 (626) 350-0537
- Fax+1 (626) 454-1667
- Websitehttps://www.fulgentgenetics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning Rock Biotech Ltd (ADR) | 78.19m | -17.58m | 236.54m | 674.00 | -- | 2.97 | -- | 3.03 | -1.68 | -1.68 | 7.33 | 7.40 | 0.6002 | 2.41 | 2.79 | 116,010.30 | -13.50 | -37.64 | -18.61 | -45.81 | 73.02 | 69.83 | -22.48 | -124.32 | 2.91 | -- | 0.0036 | -- | -4.02 | 6.21 | 46.97 | -- | -33.43 | -- |
| Oncology Institute Inc | 461.04m | -54.66m | 280.39m | 825.00 | -- | -- | -- | 0.6082 | -0.643 | -0.643 | 5.37 | -0.1258 | 2.69 | 27.10 | 8.08 | 558,835.10 | -38.67 | -20.19 | -57.52 | -24.68 | 14.82 | 17.89 | -14.38 | -12.70 | 1.39 | -3.27 | 1.19 | -- | 21.33 | 20.41 | 21.91 | -- | 25.76 | -- |
| Agilon Health Inc | 5.93bn | -405.35m | 289.79m | 856.00 | -- | 2.29 | -- | 0.0489 | -0.9782 | -0.9443 | 14.33 | 0.3056 | 3.95 | -- | 7.02 | 6,930,580.00 | -26.98 | -17.42 | -104.37 | -33.80 | -0.7641 | 4.64 | -6.83 | -6.56 | -- | -49.68 | 0.2164 | -- | -2.11 | 37.24 | -61.93 | -- | 78.94 | -- |
| Viemed Healthcare Inc | 254.79m | 13.61m | 345.20m | 1.18k | 27.38 | 2.58 | 8.33 | 1.35 | 0.3316 | 0.3316 | 6.20 | 3.51 | 1.37 | 22.40 | 9.36 | 216,110.30 | 7.52 | 10.84 | 9.73 | 13.49 | 57.89 | 60.94 | 5.49 | 8.63 | 1.01 | 18.03 | 0.135 | 0.00 | 22.54 | 22.82 | 9.98 | 5.73 | 23.06 | -- |
| Fulgent Genetics Inc | 322.67m | -60.51m | 436.92m | 1.32k | -- | 0.391 | -- | 1.35 | -1.97 | -1.97 | 10.48 | 35.78 | 0.2652 | -- | 4.20 | 245,377.20 | -5.07 | 5.99 | -5.39 | 6.46 | 40.56 | 59.30 | -19.10 | 14.51 | -- | -- | 0.0025 | 0.00 | 13.83 | -5.21 | -41.69 | -- | -8.47 | -- |
| QDM International Inc | 17.11m | 5.52m | 440.45m | 9.00 | 79.33 | 39.35 | 79.29 | 25.74 | 0.6429 | 0.6429 | 1.99 | 1.30 | 1.51 | -- | 12.48 | 1,900,989.00 | 48.66 | -- | 65.20 | -- | 51.96 | -- | 32.27 | -- | -- | 1,130.31 | 0.00 | -- | 31.65 | -- | 208.29 | -- | -- | -- |
| Community Health Systems Inc | 12.49bn | 509.00m | 475.49m | 57.00k | 0.9122 | -- | 0.4307 | 0.0381 | 3.76 | 3.76 | 92.58 | -10.06 | 0.9161 | 5.71 | 5.72 | 219,035.10 | 4.96 | 1.20 | 6.27 | 1.50 | 85.07 | 84.21 | 5.41 | 1.41 | 1.32 | 1.27 | 1.09 | 0.00 | -1.18 | 1.15 | 198.64 | -0.0784 | -5.31 | -- |
| Charming Medical Ltd | 6.22m | 1.20m | 497.22m | 49.00 | 414.68 | 10,097.79 | 339.97 | 79.92 | 0.0708 | 0.0708 | 0.3673 | 0.0029 | -- | -- | -- | 126,974.50 | -- | -- | -- | -- | 99.75 | -- | 19.27 | -- | 0.675 | -- | 0.8968 | -- | 3.43 | -- | 54.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.01m | 6.58% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 1.19m | 3.87% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.10m | 3.59% |
| Millennium Management LLCas of 31 Dec 2025 | 939.38k | 3.07% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 841.49k | 2.75% |
| RTW Investments LPas of 31 Dec 2025 | 705.03k | 2.30% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 701.31k | 2.29% |
| Geode Capital Management LLCas of 31 Dec 2025 | 508.22k | 1.66% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2025 | 499.51k | 1.63% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 493.66k | 1.61% |
